Drug Stock On Track For Best Day Ever After Development Deal

Voyager Therapeutics is the top stock on the Nasdaq this morning

Managing Editor
Jan 29, 2019 at 9:45 AM
facebook twitter linkedin


The shares of Voyager Therapeutics Inc (NASDAQ:VYGR) are up 44% to trade at $11.58 this morning, after the gene therapy specialist inked a development deal with Neurocrine Biosciences (NBIX). The deal will focus on Parkinson's disease and Friedreich's ataxia treatments, and Voyager could get up to $1.7 billion in potential milestone payments on top of the $165 million received up front.

Voyager Therapeutics stock sits at the top of the Nasdaq today, and is on track for its best day ever. VYGR desperately needed this shot in the arm. The stock had carved out a channel of lower lows for the last six months, culminating in a Jan. 24 record bottom of $7.76. Now, the shares have toppled their formerly restrictive 50-day moving average for the first time since an early September bear gap.

Analysts have remained bullish, however. By the numbers, six of the nine in coverage have "strong buy" recommendations on the security. Even more revealing, the average 12-month price target stands all the way up at $24.55.

In the options pits, there has been a distinct preference toward calls -- though it's been amid very low absolute volumes. VYGR has a Schaeffer's put/call open interest ratio (SOIR) of 0.10, in the 2nd percentile of its annual range. In other words, short-term options traders are much more call-skewed than normal.

 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Stock Pick Report
 


 


 
Special Offers from Schaeffer's Trading Partners